

Contents

Editors	ix
Contributors	xi
Reviewers	xiii
Abbreviations	xiv
Acknowledgements	xvii
Introduction	xviii
1 Risk Factors	1
Why Should Oncologists Worry About Risk Factors?	1
Measurement of Risk	1
Causation	2
Conclusions	10
Further Reading	10
References	10
2 Screening	13
Introduction	13
The Benefit of Screening	13
The Harms of Screening: Overdiagnosis	19
Cost-effectiveness of Breast Cancer Screening Programmes	22
Conclusions	24
Further Reading	24
References	25
3 Prognosis	29
Introduction	29
Factors Influencing Cancer Survival	29

	Improvement Over Time	32
	Prognosis and Survival	32
	Cancer Prognosis in Trials Versus Observational Studies	36
	Types of Bias	37
	Conclusions	40
	References	40
4	Cancer Registries	43
	Introduction	43
	Notification and Completeness of Cancer Registries	43
	Minimal Data Set	45
	Supplementary Items	47
	Coding Rules	47
	Follow-up	49
	Epidemiological Studies with Cancer Registry Data	50
	Quality of Care Studies with Cancer Registry Data	51
	Conclusions	52
	References	53
5	Drug Development (Including Phase I Trials)	55
	Introduction	55
	Strategies in Drug Development	56
	Target Discovery Precedes Drug Discovery	57
	Small Molecule Drug Discovery: Synthesis and Optimisation	58
	Selection of a Drug: Preclinical Assays	60
	Development of Anticancer Biologics	64
	Towards Phase I Clinical Trials	65
	Phase I Studies	66
	Conclusions	68
	Further Reading	69
	References	69
6	Randomised Trials	71
	Introduction	71
	Using Systematic Reviews When Designing a Randomised Trial	72
	Formulating the Question for a Randomised Trial	72
	Eligibility Criteria	73

Outcome Selection	75
Sample Size	76
Randomising Patients	77
Blinding or Masking	81
Statistical Analysis	82
Reporting	82
Conclusions	83
Further Reading	84
References	84
7 Choice of Outcomes (Including Core Outcome Sets and Surrogate Outcomes)	87
Outcomes (or Endpoints)	87
Primary and Secondary Endpoints	88
Core Outcome Sets	88
Categories of Outcomes	89
Surrogate Endpoints	91
Endpoint Definition	92
Most Common Individual Outcomes Used in Oncology Clinical Trials	95
Conclusions	98
Further Reading	99
References	100
8 Statistical Issues (Including Subgroups, Time-To-Event Analyses, Multiplicity)	104
Introduction	104
Are the Data Adequately Described?	105
Which Quantities Have Been Estimated?	109
Which Statistical Tests Have Been Performed?	110
How is the Type-I Error Controlled?	111
Is the Statistical Power Adequate?	112
Subgroup Analyses	115
Conclusions	117
Further Reading	117
References	118

9	Systematic Reviews: A Key to Support Evidence-Informed Decision Making	119
	Introduction	119
	When is a Systematic Review Needed?	119
	Formulating the Question	122
	Defining Eligibility Criteria	122
	Search Strategy	125
	Study Selection	127
	Assessing the Quality of the Studies and the Body of Evidence	127
	Data Extraction from Studies	128
	Synthesis	129
	Conclusions	132
	Further Reading and Resources	132
	References	133
10	Clinical Research in Rare Cancers	135
	Introduction	135
	Challenges and Limitations in Clinical Research in Rare Cancers	136
	Future Directions for Clinical Research in Rare Cancers	137
	Conclusions	143
	Further Reading	144
	References	144
11	How to Become a Researcher	146
	Introduction	146
	Case Study 1: Marco	146
	Case Study 2: Florence	151
	Conclusions	153
	Further Reading	154
	Glossary	155
	Index	171